Mehmet Ali Deveci

Mehmet Ali Deveci

Auto-generated profile, based on publicly available information

Mehmet Ali Deveci

Department of Orthopaedics and Traumatology, Koç University, İstanbul, Türkiye

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2016 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
SPSemra Paydas
Semra Paydas
EBEmine Kilic Bagir
Emine Kilic Bagir
MDMehmet Ali Deveci
Mehmet Ali Deveci
GGGulfiliz Gonlusen
Gulfiliz Gonlusen

1 January 2017 in Acta Orthopaedica et Traumatologica Turcica
Verified
Journal Article
Open access
MDMehmet Ali Deveci
Mehmet Ali Deveci
SPSemra Paydaş
Semra Paydaş
GGGülfiliz Gönlüşen
Gülfiliz Gönlüşen
CÖCenk Özkan
Cenk Özkan
ÖBÖmer Biçer
Ömer Biçer
MTMustafa Tekin
Mustafa Tekin
Objective: Giant cell tumor of bone (GCT) is a primary, osteolytic, benign tumor of the bone. Surgery is the commonly used treatment; however, recurrence remains a problem. Receptor activator of nuclear factor kappa B (RANKL) is responsible for the formation of osteoclastic cells. Discovery of RANKL and its human monoclonal antibody, denosumab, led to use of denosumab for treatment of GCT. The aim of this study was to evaluate clinical and pathological results of treatment of GCT with denosumab and to assess adverse effect profile and recurrence rate. Methods: Thirteen patients with 14 lesions were enrolled in the study. Mean age was 38.3 years. Patients were given subcutaneous injections of denosumab (120 mg) every 4 weeks (with additional doses on days 0, 8 and 15 in cycle 1 only) and were radiologically evaluated for tumor response. Pain and functional status were measured using Visual Analog Score (VAS) and Musculoskeletal Tumor Society Score (MSTS). Adverse effects were analyzed after each cycle. Results: Participants were 5 men and 8 women. Mean follow-up was 17 months. One lesion was Campanacci grade I, 8 were grade II, and 5 were grade III. Eight lesions were recurrent, and remaining were primary lesions. After average of 9 cycles (range: 4e17 cycles), all tumors underwent radiological regression. Ten lesions were removed surgically. More than 90% of giant cells were found to have regressed in all pathological specimens. On last follow-up, average VAS was 1 and MSTS was 87%. Fatigue and joint and muscle pain after injections was reported by 46% of patients, and mild hypocalcaemia was seen in 1 patient. Conclusion: Denosumab has been shown to be a successful drug in treatment of GCT. Denosumab can be used as neoadjuvant for all recurrent lesions, grade II lesions with high surgical risk, grade III lesions, and metastatic cases of GCT. Level of evidence: Level IV, Therapeutic study

1 December 2009 in Injury
Verified
Journal Article
Closed access
EEErdinç Esen
Erdinç Esen
YDYunus Doğramacı
Yunus Doğramacı
SGSerap Gültekin
Serap Gültekin
MDMehmet Ali Deveci
Mehmet Ali Deveci
FSFatih Suluova
Fatih Suluova
SBSelçuk Bölükbaşı
Selçuk Bölükbaşı

1 January 2017 in Acta Orthopaedica et Traumatologica Turcica
Verified
Journal Article
Open access
MDMehmet Ali Deveci
Mehmet Ali Deveci
HÖHilmi Özbarlas
Hilmi Özbarlas
KAKivilcim Ates
Kivilcim Ates
ÖBÖmer Biçer
Ömer Biçer
MTMustafa Tekin
Mustafa Tekin
CÖCenk Özkan
Cenk Özkan
Objective: Elastofibroma dorsi (ED) is a rare, benign, soft tissue tumor typically located between inferior corner of scapula and posterior chest wall causing mass, scapular snapping, and pain. When classic symptoms and localization are present, it is diagnosed without biopsy and treated with marginal resection. This study retrospectively analyzed patients operated on for ED to evaluate presenting symptoms, tumor size, complications, and clinical results, and to suggest optimal treatments. Methods: This study included 51 patients who underwent surgery for ED in 2 different clinics between 2005 and 2015. Patient age, gender, profession, side affected, symptoms, average duration of symptoms, and tumor size were researched. Radiological examinations of patients were evaluated. Patients with lesions larger than 5 cm in size were operated on. Postoperative complications, recurrence, and functional results were evaluated using Constant score and compared to preoperative values. Results: A total of 61 operated lesions of 51 patients clinically and radiologically diagnosed with ED were retrospectively evaluated. Average length of time patient experienced symptoms was 11.21 months. Lesions in 19 (37.2%) patients were bilateral, 10 of which were symptomatic and larger than 5 cm in size, meeting indication for surgery. Average lesion diameter was 8.7 cm. Average follow-up was 26.89 months. Average of preoperative Constant score of 67.28 subsequently increased to 92.88 (p < 0.05). Seroma and hematoma were observed in 11.5% of patients. Conclusion: Generally, good clinical results can be obtained with marginal resection without requiring a biopsy, considering classic complaints and radiological appearance of ED. Level of evidence: Level IV, Therapeutic study.

6 April 2011 in European Journal of Orthopaedic Surgery & Traumatology
Verified
Journal Article
Closed access
PDF file
EAErdem Aktas
Erdem Aktas
ESErtugrul Sener
Ertugrul Sener
OZOzlem Zengin
Ozlem Zengin
PGPinar Uyar Gocun
Pinar Uyar Gocun
MDMehmet Ali Deveci
Mehmet Ali Deveci

6 January 2016 in Acta Orthopaedica et Traumatologica Turcica
Verified
Journal Article
Open access
AAAhmet Ateş
Ahmet Ateş
HGHalil Can Gemalmaz
Halil Can Gemalmaz
MDMehmet Ali Deveci
Mehmet Ali Deveci
SŞSezai Aykın Şimşek
Sezai Aykın Şimşek
EÇEngin Çetin
Engin Çetin
AŞAlpaslan Şenköylü
Alpaslan Şenköylü
Objective: The aim of this study was to compare the functional and radiological outcomes of vertebroplasty and kyphoplasty in patients with osteoporotic vertebra fractures. Methods: The files of the patients who underwent vertebroplasty or kyphoplasty for osteoporotic vertebrae fractures were retrieved from the archives. Forty-three patients with complete follow-up data were included in the study group. The patients were evaluated for radiological outcomes in terms of local kyphosis angle, wedging index, compression ratio, visual analog pain scale (VAS) and Oswestry Disability Index (ODI). Results: In the study group, kyphoplasty was performed on 24 vertebrae of 22 patients (17 females, 5 males; mean age: 73 years) whereas vertebroplasty was applied on 24 vertebrae of 21 (16 females, 5 males; mean age: 74.7 years) patients. The mean follow-up time was 26 months. When the VAS and ODI values of the groups were analyzed, both groups showed statistically significant progress after the operation. Radiological data showed that the kyphoplasty group showed statistically significant improvement in the sagittal index values whereas the vertebroplasty group did not. The overall complication ratio was 4%. Conclusion: Both vertebroplasty and kyphoplasty are effective treatment methods for functional recovery and pain relief in osteoporotic fractures of the vertebra. Although radiological outcomes of the kyphoplasty seem to be better, this does not have any clinical relevance. We suggest vertebroplasty over kyphoplasty since it is an easier method to manage. Level of evidence: Level III, Therapeutic study.